Zdrowie i gospodarka · 28/07/2026
FDA Amends Fee Rate for Using Priority Review Voucher in Fiscal Year 2026
The FDA is updating a notice to reflect changes made by Congress in February 2026, which require sponsors of human drug applications using rare pediatric disease priority review vouchers to submit a priority review user fee upon application submission.